Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung

Inclusion Criteria: * Histologically proven, Progressive or recurrent high grade osteosarcoma metastatic to the lung * Patients with histologically proven, fully malignant high-grade osteosarcoma of bone * Measureable pulmonary metastases * Less than grade 3 neuropathies, insignificant decreases in cardiac or auditory function * ECOG performance status of 0, 1 or 2 * FEV1 of 50% or greater of predicted value * FEV1/FVC ratio of 65% or greater * Serum creatinine of ≤ 1.5 mg/dl * Total bilirubin ≤ 1.5mg/dl and SGOT or SGPT \< 2.5 times upper normal limit * ANC of ≥ 1,000/mm3 and platelet count of ≥ 100,000/mm3 Exclusion Criteria: * Grade 3 or higher painful neuropathy persisting after a prior platinum containing regimen * Patients who are pregnant or are of childbearing potential and not using methods to avoid pregnancy * Concurrent systemic chemotherapy * Greater than Grade 2 pulmonary toxicity * Pulmonary atelectasis * Reactive airway disease which has resulted in hospitalization within the last year or which requires daily treatment with bronchodilator therapy * Concurrent serious infections * Unstable or serious concurrent medical condition * Recent major surgery or thoracic radiation therapy or chemotherapy * Significant pulmonary fibrosis secondary to prior radiation * Major ventilatory distribution abnormalities * Osteosarcoma secondary to radiation or premalignant conditions * History of prior malignancy * Low grade osteosarcoma, parosteal or periosteal sarcoma